Summit Therapeutics Inc

NASDAQ:SMMTUnited States

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.

Contact Information

Headquarters

2882 Sand Hill Road, Suite 106MENLO PARK, CA, United States 94025

Phone

650-460-8308

Fax

302-655-5049

Executives

Executive Chairman of the Board, Co-Chief Executive Officer

Robert Duggan

President, Co-Chief Executive Officer, Director

Mahkam Zanganeh

Chief Financial Officer

Ankur Dhingra

Chief Operating Officer, Director

Manmeet Soni

Lead Non-Executive Independent Director

Kenneth Clark